Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study

November 21, 2024

View Press Release Corporate presentation Contact us
Previous